Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 3.8% – Time to Sell?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s stock price dropped 3.8% during mid-day trading on Thursday . The stock traded as low as $2.23 and last traded at $2.27. 556,419 shares changed hands during mid-day trading, an increase of 43% from the average session volume of 390,083 shares. The stock had previously closed at $2.36.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NAUT. Guggenheim increased their price target on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $4.00.

Nautilus Biotechnology Stock Down 11.9%

The firm has a market cap of $254.16 million, a P/E ratio of -4.35 and a beta of 0.75. The firm has a fifty day moving average of $2.55 and a 200-day moving average of $2.47.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings results on Tuesday, April 28th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.

Insider Activity

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of Nautilus Biotechnology stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total value of $11,750,000.00. Following the transaction, the insider directly owned 971,885 shares of the company’s stock, valued at $2,283,929.75. The trade was a 83.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 41.10% of the company’s stock.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of large investors have recently modified their holdings of the company. Sentinel Trust Co. LBA acquired a new position in shares of Nautilus Biotechnology during the fourth quarter valued at about $1,462,000. Jane Street Group LLC lifted its position in shares of Nautilus Biotechnology by 304.1% during the second quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock valued at $210,000 after purchasing an additional 218,512 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Nautilus Biotechnology during the fourth quarter worth about $204,000. Jacobs Levy Equity Management Inc. bought a new stake in Nautilus Biotechnology in the 1st quarter worth about $194,000. Finally, Squarepoint Ops LLC grew its position in Nautilus Biotechnology by 29.5% in the 3rd quarter. Squarepoint Ops LLC now owns 131,827 shares of the company’s stock worth $111,000 after purchasing an additional 30,005 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.